Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
Rhythm Pharmaceuticals, the commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, announced it will report its Q1 2026 financial results on May 5, 2026, and participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. Their lead product, IMCIVREE (setmelanotide), is approve…